OrthoPediatrics Corp. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 8, 2024. OrthoPediatrics designs and sells pediatric orthopedic implants, instruments and specialty braces; it reported one operating segment.
Business context and reporting period
The company markets 53 surgical and bracing systems across trauma and deformity, scoliosis, and sports medicine/other. It sells in the United States and more than 70 countries internationally, relying substantially on independent sales agencies and distributors. Approximately 66% of 2023 revenue came through sales agencies. Revenue is seasonal, typically higher during summer and school-holiday periods.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $148.7 million | $122.3 million |
| Gross profit / margin | $111.3 million / 75% | $90.7 million / 74% |
| Operating loss | $26.8 million | $25.4 million |
| Net income (loss) | $(21.0) million | $1.3 million |
| Net income (loss) per diluted share | $(0.92) | $0.06 |
| Cash used in operating activities | $27.0 million | $21.8 million |
At year-end, cash and cash equivalents were $31.1 million, restricted cash $2.0 million, and short-term investments $49.3 million—$82.3 million combined. Total assets were $438.7 million, total liabilities $61.7 million, and stockholders’ equity $377.0 million. Inventory was $105.9 million, up from $78.2 million, and trade receivables were $34.6 million, up from $24.8 million.
The company reported $10.3 million of term-loan principal and final payment, plus a $0.8 million mortgage payable to an affiliate, before debt discounts and current-maturity presentation. The December 2023 MidCap agreement provides up to $50 million of revolving credit and up to $30 million of term loans; the first $10 million term tranche was drawn. The facility carries minimum interest rates of 9.0% on term loans and 6.5% on revolving loans, and includes trailing-twelve-month revenue covenants. The company reported compliance at year-end.
Material changes versus the prior period
- Revenue grew 22% ($26.4 million); management attributed growth to broader market share and $5.3 million of sales growth from acquired businesses. U.S. revenue was $111.0 million (+20%) and international revenue $37.7 million (+26%).
- Trauma and deformity revenue rose 26% to $106.8 million; scoliosis rose 13% to $37.9 million; sports medicine/other rose 6% to $4.0 million.
- Despite revenue growth, the company moved from net income in 2022 to a net loss in 2023. Operating loss widened modestly, while other income fell to $5.4 million from $21.7 million, primarily because the ApiFix contingent-consideration fair-value gain was $3.0 million versus $25.9 million in 2022.
- Operating cash outflow increased, mainly reflecting working-capital use, including a $26.3 million increase in inventory and a $9.7 million increase in receivables. Capital spending was $16.9 million, primarily for consigned instrument sets.
- General and administrative expense increased 27% to $75.4 million, and research and development expense increased 27% to $10.2 million. The company recorded a $1.0 million ApiFix trademark impairment, compared with $3.6 million in 2022.
Outlook, risks, contingencies and unusual items
The filing gives no numerical revenue or earnings guidance. Management expects near-term losses to continue while investing in product development, sales infrastructure and consigned instrument sets. It says existing cash, credit availability and anticipated product receipts should cover expected cash requirements for at least 12 months.
Pipeline milestones described by management include a full-scale launch of the Pediatric Nailing Platform | Tibia in the first half of 2024; planned 2024 beta/full launches for the RESPONSE Rib and Pelvic System; and a 2024 beta launch, with full-scale launch expected in 2025, for VerteGlide. Active Growing Implants remain in development. These are expectations, not guaranteed outcomes.
- Management said RSV-related hospital capacity constraints negatively affected elective procedures and sales in 2023 and 2022; future effects remain uncertain. The filing also cites inflation, interest rates, economic conditions and geopolitical events as potential pressures.
- Key risks include ongoing operating losses, reliance on third-party manufacturers and sales channels, inventory obsolescence and working-capital demands, competition, limited published long-term clinical outcomes, reimbursement changes, and extensive medical-device regulation. MDR certification requirements in Europe and UK regulatory requirements are also relevant market-access risks.
- ApiFix revenue forecasts were reduced, prompting trademark impairments in both 2023 and 2022. Three other trademarks had fair values less than 15% above carrying values at the last review, making their estimates sensitive to assumptions.
- The IMED Surgical software-ownership dispute remained unresolved in the filing; the court set a March 13, 2024 show-cause deadline for the plaintiff concerning arbitration. The Wishbone litigation was settled and dismissed with prejudice; the payment to OrthoPediatrics was described as immaterial.
- On January 5, 2024, after year-end, the company acquired Boston Brace for $22 million in cash, subject to customary adjustments, and granted approximately 83,000 restricted shares valued at about $2.5 million. Boston Brace is involved in a wrongful-death lawsuit with trial scheduled for December 2025.
- The 2023 audit opinion was unqualified, and the auditor and management concluded internal control over financial reporting was effective. The auditor identified trademark impairment valuation as a critical audit matter. The company reported no cybersecurity incident that materially affected it.
Important facts for investors to verify
- Whether revenue growth and planned product launches translate into improved operating performance and a path toward profitability.
- Whether cash burn, inventory and receivables growth, and investment in instrument sets remain manageable; confirm actual borrowing and covenant headroom under the MidCap facility.
- How much of growth reflects underlying demand versus acquisitions, and whether acquired products and the Boston Brace acquisition integrate and perform as expected.
- Whether ApiFix and other trademark valuations, contingent acquisition payments, and the Boston Brace litigation create further charges or obligations.
- Whether RSV-related procedure delays, regulatory approvals, reimbursement, or distributor concentration materially affect demand and international expansion.